Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.

Wojcik CM, Rao SM, Schembri AJ, Drake AS, Maruff P, Schindler D, Alberts J, Yasin F, Pol J, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287. [Epub ahead of print]

PMID:
30465463
2.

Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models.

Humeau J, Lévesque S, Kroemer G, Pol JG.

Methods Mol Biol. 2019;1884:297-315. doi: 10.1007/978-1-4939-8885-3_21.

PMID:
30465212
3.

How community pharmacists prioritize cognitive pharmaceutical services.

van de Pol JM, Koster ES, Hövels AM, Bouvy ML.

Res Social Adm Pharm. 2018 Sep 26. pii: S1551-7411(18)30704-6. doi: 10.1016/j.sapharm.2018.09.012. [Epub ahead of print]

PMID:
30429104
4.

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts.

Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 6;7(10):e1484980. doi: 10.1080/2162402X.2018.1484980. eCollection 2018.

5.

Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.

Gujar S, Pol JG, Kroemer G.

Oncoimmunology. 2018 Mar 13;7(8):e1442169. doi: 10.1080/2162402X.2018.1442169. eCollection 2018.

6.

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y.

Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040.

7.

Metabolic vulnerability of cisplatin-resistant cancers.

Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, Joseph A, Astesana V, Pietrocola F, Wu GS, Castedo M, Kroemer G.

EMBO J. 2018 Jul 13;37(14). pii: e98597. doi: 10.15252/embj.201798597. Epub 2018 Jun 6.

PMID:
29875130
8.

Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.

Cruickshank B, Giacomantonio M, Marcato P, McFarland S, Pol J, Gujar S.

Front Immunol. 2018 Apr 3;9:654. doi: 10.3389/fimmu.2018.00654. eCollection 2018. Review.

9.

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.

Pol J, Kroemer G.

Cell Res. 2018 May;28(5):501-502. doi: 10.1038/s41422-018-0031-9. Epub 2018 Mar 28. No abstract available.

PMID:
29593340
10.

Pharmacy in transition: A work sampling study of community pharmacists using smartphone technology.

van de Pol JM, Geljon JG, Belitser SV, Frederix GWJ, Hövels AM, Bouvy ML.

Res Social Adm Pharm. 2019 Jan;15(1):70-76. doi: 10.1016/j.sapharm.2018.03.004. Epub 2018 Mar 9.

11.

TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.

Loef M, Kroon FPB, Bergstra SA, van der Pol JA, Lems WF, Kerstens PJSM, Allaart CF, Kloppenburg M.

Rheumatology (Oxford). 2018 Nov 1;57(11):1917-1924. doi: 10.1093/rheumatology/key016.

PMID:
29471377
12.

Uncomplicated 90Y Selective Internal Radio Therapy in a Patient With Hepatocellular Carcinoma After Arterial and Portal Vein Embolizations.

van der Pol J, de Vos-Geelen J, Bucerius J, Mitea C, van der Leij C.

Clin Nucl Med. 2018 Mar;43(3):180-182. doi: 10.1097/RLU.0000000000001945.

PMID:
29389772
13.

Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.

Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G.

Trends Immunol. 2018 Mar;39(3):209-221. doi: 10.1016/j.it.2017.11.006. Epub 2017 Dec 20. Review.

PMID:
29275092
14.

Trial watch: DNA-based vaccines for oncological indications.

Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L.

Oncoimmunology. 2017 Nov 20;6(12):e1398878. doi: 10.1080/2162402X.2017.1398878. eCollection 2017. Review.

15.

New Food Baits for Trapping German Cockroaches, Blattella germanica (L.) (Dictyoptera: Blattellidae).

Pol JC, Jimenez SI, Gries G.

J Econ Entomol. 2017 Dec 5;110(6):2518-2526. doi: 10.1093/jee/tox247.

PMID:
29029107
16.

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Bloy N, Garcia P, Laumont CM, Pitt JM, Sistigu A, Stoll G, Yamazaki T, Bonneil E, Buqué A, Humeau J, Drijfhout JW, Meurice G, Walter S, Fritsche J, Weinschenk T, Rammensee HG, Melief C, Thibault P, Perreault C, Pol J, Zitvogel L, Senovilla L, Kroemer G.

Immunol Rev. 2017 Nov;280(1):165-174. doi: 10.1111/imr.12582. Review.

PMID:
29027230
17.

Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.

18.

Is optimising gout treatment the key to closing the mortality gap in gout patients?

Ten Brinck RM, de Moel EC, van der Pol JA, van Beest S, de Koning A, Huizinga TWJ.

Ann Rheum Dis. 2018 Jan;77(1):e2. doi: 10.1136/annrheumdis-2017-211638. Epub 2017 May 25. No abstract available.

PMID:
28546256
19.

The impact of demand management strategies on parents' decision-making for out-of-hours primary care: findings from a survey in The Netherlands.

Giesen MJ, Keizer E, van de Pol J, Knoben J, Wensing M, Giesen P.

BMJ Open. 2017 May 9;7(5):e014605. doi: 10.1136/bmjopen-2016-014605. Erratum in: BMJ Open. 2017 Jun 26;7(6):e014605corr1.

20.

Gut Colonization by Methanogenic Archaea Is Associated with Organic Dairy Consumption in Children.

van de Pol JA, van Best N, Mbakwa CA, Thijs C, Savelkoul PH, Arts IC, Hornef MW, Mommers M, Penders J.

Front Microbiol. 2017 Mar 10;8:355. doi: 10.3389/fmicb.2017.00355. eCollection 2017.

21.

Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review.

van der Pol J, Vöö S, Bucerius J, Mottaghy FM.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1234-1243. doi: 10.1007/s00259-017-3675-7. Epub 2017 Mar 16. Review.

22.

Visible-Light Excitation of a Molecular Motor with an Extended Aromatic Core.

van Leeuwen T, Pol J, Roke D, Wezenberg SJ, Feringa BL.

Org Lett. 2017 Mar 17;19(6):1402-1405. doi: 10.1021/acs.orglett.7b00317. Epub 2017 Mar 1.

23.

Crystalline inclusions in myeloma cells: Need to go beyond morphologic curiosity.

Agashe SR, Pol JN, Kadkol GA, Patil PP.

Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):139-140. doi: 10.4103/0377-4929.200036. No abstract available.

24.

Metabolic effects of fasting on human and mouse blood in vivo.

Pietrocola F, Demont Y, Castoldi F, Enot D, Durand S, Semeraro M, Baracco EE, Pol J, Bravo-San Pedro JM, Bordenave C, Levesque S, Humeau J, Chery A, Métivier D, Madeo F, Maiuri MC, Kroemer G.

Autophagy. 2017 Mar 4;13(3):567-578. doi: 10.1080/15548627.2016.1271513. Epub 2017 Jan 6.

25.

Positive vs. Negative: The Impact of Question Polarity in Voting Advice Applications.

Holleman B, Kamoen N, Krouwel A, Pol JV, Vreese C.

PLoS One. 2016 Oct 10;11(10):e0164184. doi: 10.1371/journal.pone.0164184. eCollection 2016.

26.

Fasting improves anticancer immunosurveillance via autophagy induction in malignant cells.

Pietrocola F, Pol J, Kroemer G.

Cell Cycle. 2016 Dec 16;15(24):3327-3328. doi: 10.1080/15384101.2016.1224797. Epub 2016 Sep 2. No abstract available.

27.

Autophagy induction for the treatment of cancer.

Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Maiuri MC, Madeo F, Kroemer G.

Autophagy. 2016 Oct 2;12(10):1962-1964. Epub 2016 Aug 17.

28.

Modelling with ANIMO: between fuzzy logic and differential equations.

Schivo S, Scholma J, van der Vet PE, Karperien M, Post JN, van de Pol J, Langerak R.

BMC Syst Biol. 2016 Jul 27;10(1):56. doi: 10.1186/s12918-016-0286-z.

29.

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G.

Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.

30.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2016 Jun 1;196(11):4587-95. doi: 10.4049/jimmunol.1600106. Epub 2016 Apr 27.

31.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

32.

S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ESY, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD.

Nat Immunol. 2016 May;17(5):514-522. doi: 10.1038/ni.3433. Epub 2016 Apr 4.

33.

First oncolytic virus approved for melanoma immunotherapy.

Pol J, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(1):e1115641. eCollection 2016.

34.

Age-related changes in the lateral lipid distribution in a human lens described by mass spectrometry imaging.

Pol J, Faltyskova H, Krasny L, Volný M, Vlacil O, Hajduch M, Lemr K, Havlicek V.

Eur J Mass Spectrom (Chichester). 2015;21(3):297-303. doi: 10.1255/ejms.1350.

PMID:
26307709
35.

Trial Watch: Peptide-based anticancer vaccines.

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Jan 9;4(4):e974411. eCollection 2015 Apr. Review.

36.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.

37.

Documented atrial fibrillation recurrences after pulmonary vein isolation are associated with diminished quality of life.

Berger WR, Krul SP, van der Pol JA, van Dessel PF, Conrath CE, Wilde AA, de Groot JR.

J Cardiovasc Med (Hagerstown). 2016 Mar;17(3):201-8. doi: 10.2459/JCM.0000000000000274.

PMID:
25955303
38.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Feb 3;4(1):e985940. eCollection 2015 Jan. Review.

39.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

40.

Trial Watch: Radioimmunotherapy for oncological indications.

Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e954929. eCollection 2014 Oct. Review.

41.

Trial watch: Dendritic cell-based anticancer therapy.

Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 21;3(11):e963424. eCollection 2014 Nov. Review.

42.

Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation.

Pol JG, Lekbaby B, Redelsperger F, Klamer S, Mandouri Y, Ahodantin J, Bieche I, Lefevre M, Souque P, Charneau P, Gadessaud N, Kremsdorf D, Soussan P.

FASEB J. 2015 May;29(5):1879-89. doi: 10.1096/fj.14-258715. Epub 2015 Jan 28.

PMID:
25630972
43.

Ultrasonography - A diagnostic modality for oral and maxillofacial diseases.

Joshi PS, Pol J, Sudesh AS.

Contemp Clin Dent. 2014 Jul;5(3):345-51. doi: 10.4103/0976-237X.137942.

44.

Trial Watch:: Oncolytic viruses for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 1;3:e28694. eCollection 2014. Review.

45.

Modeling biological pathway dynamics with timed automata.

Schivo S, Scholma J, Wanders B, Urquidi Camacho RA, van der Vet PE, Karperien M, Langerak R, van de Pol J, Post JN.

IEEE J Biomed Health Inform. 2014 May;18(3):832-9. doi: 10.1109/JBHI.2013.2292880.

PMID:
24808226
46.

Trial Watch: DNA vaccines for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e28185. Epub 2014 Apr 1. Review.

47.

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL.

Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.

48.

Irradiation of existing atherosclerotic lesions increased inflammation by favoring pro-inflammatory macrophages.

Gabriels K, Hoving S, Gijbels MJ, Pol JF, te Poele JA, Biessen EA, Daemen MJ, Stewart FA, Heeneman S.

Radiother Oncol. 2014 Mar;110(3):455-60. doi: 10.1016/j.radonc.2014.01.006. Epub 2014 Mar 11.

PMID:
24630533
49.

Retention of 99mTc-DMSA(III) and 99mTc-nanocolloid in different syringes affects imaging quality.

Bauwens M, Pooters I, van der Pol J, Mottaghy FM, van Kroonenburgh M.

Nucl Med Commun. 2014 Apr;35(4):433-7. doi: 10.1097/MNM.0000000000000073.

PMID:
24569706
50.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

Supplemental Content

Support Center